GlassScriptPhysician profile
Ravindranath Nallamothu
NPI 1679724033
$3,919.48
in general payments reported to CMS, 2019-2025
14 companies · $3,104 in 2025
The $3,104 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $80.29 · 2021: $194 · 2022: $107 · 2023: $48.66 · 2024: $174 · 2025: $3,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $326.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $3,000.00 | 2025 | |
| Pfizer INC. | $172.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $144.47 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $138.76 | 2019-2024 | Eliquis |
| Gilead Sciences, INC. | $102.47 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $95.70 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.45 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Sunovion Pharmaceuticals INC. | $62.88 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.07 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $24.00 | 2025 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $20.55 | 2025 | Edarbi |
| Lantheus Medical Imaging, INC. | $16.81 | 2019 | |
| Novo Nordisk INC | $15.98 | 2025 | Ozempic, Rybelsus |
| Allergan, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravindranath Nallamothu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.